288 related articles for article (PubMed ID: 30732676)
1. NOTCH3 Overexpression and Posttranscriptional Regulation by miR-150 Were Associated With EGFR-TKI Resistance in Lung Adenocarcinoma.
Zhang Y; Chen B; Wang Y; Zhao Q; Wu W; Zhang P; Miao L; Sun S
Oncol Res; 2019 Jul; 27(7):751-761. PubMed ID: 30732676
[TBL] [Abstract][Full Text] [Related]
2. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
Lu GS; Li M; Xu CX; Wang D
Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
[TBL] [Abstract][Full Text] [Related]
3. Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties.
Si J; Ma Y; Bi JW; Xiong Y; Lv C; Li S; Wu N; Yang Y
J Exp Clin Cancer Res; 2019 Dec; 38(1):481. PubMed ID: 31801598
[TBL] [Abstract][Full Text] [Related]
4. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
[TBL] [Abstract][Full Text] [Related]
5. LncRNA SNHG15 regulates EGFR-TKI acquired resistance in lung adenocarcinoma through sponging miR-451 to upregulate MDR-1.
Huang J; Pan B; Xia G; Zhu J; Li C; Feng J
Cell Death Dis; 2020 Jul; 11(7):525. PubMed ID: 32655137
[TBL] [Abstract][Full Text] [Related]
6. Osteopontin improves sensitivity to tyrosine kinase inhibitor in lung adenocarcinoma in vitro by promoting epidermal growth factor receptor phosphorylation.
Wang YJ; Wang QW; Yu DH; Song CK; Guo ZX; Liu XP; Chen C; Yao J; Wang AF; Hu WD
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3245-3254. PubMed ID: 34255150
[TBL] [Abstract][Full Text] [Related]
7. Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma.
Song H; Liu D; Wang L; Liu K; Chen C; Wang L; Ren Y; Ju B; Zhong F; Jiang X; Wang G; Chen ZS; Zou C
Mol Cancer; 2022 Feb; 21(1):43. PubMed ID: 35144642
[TBL] [Abstract][Full Text] [Related]
8. Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma.
Kawana S; Saito R; Miki Y; Kimura Y; Abe J; Sato I; Endo M; Sugawara S; Sasano H
Cancer Med; 2021 Jan; 10(2):718-727. PubMed ID: 33305905
[TBL] [Abstract][Full Text] [Related]
9. A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop.
Wu DW; Wang YC; Wang L; Chen CY; Lee H
Theranostics; 2018; 8(5):1256-1269. PubMed ID: 29507618
[No Abstract] [Full Text] [Related]
10. Long non-coding RNA H19 confers resistance to gefitinib via miR-148b-3p/DDAH1 axis in lung adenocarcinoma.
Huang Z; Ma Y; Zhang P; Si J; Xiong Y; Yang Y
Anticancer Drugs; 2020 Jan; 31(1):44-54. PubMed ID: 31503013
[TBL] [Abstract][Full Text] [Related]
11. Construction of a circRNA-miRNA-mRNA Regulated Pathway Involved in EGFR-TKI Lung Adenocarcinoma Resistance.
Dai C; Liu B; Li S; Hong Y; Si J; Xiong Y; Wu N; Ma Y
Technol Cancer Res Treat; 2021; 20():15330338211056809. PubMed ID: 34825849
[No Abstract] [Full Text] [Related]
12. Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma.
Hong X; Hsieh MT; Tseng TY; Lin HY; Chang HC; Yau ST; Cheng WC; Ke B; Liao HH; Wu CY; Liu AA; Wu MM; Huang KY; Yang PC; Kuo SC; Hung MC; Lee PC
J Biol Chem; 2023 Jun; 299(6):104814. PubMed ID: 37178919
[TBL] [Abstract][Full Text] [Related]
13. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
[TBL] [Abstract][Full Text] [Related]
14. Hsa_circ_0005576 promotes osimertinib resistance through the miR-512-5p/IGF1R axis in lung adenocarcinoma cells.
Liu S; Jiang Z; Xiao P; Li X; Chen Y; Tang H; Chai Y; Liu Y; Zhu Z; Xie Q; He W; Ma Y; Jin L; Feng W
Cancer Sci; 2022 Jan; 113(1):79-90. PubMed ID: 34706132
[TBL] [Abstract][Full Text] [Related]
15. Targeting YAP-p62 signaling axis suppresses the EGFR-TKI-resistant lung adenocarcinoma.
Park HS; Lee DH; Kang DH; Yeo MK; Bae G; Lee D; Yoo G; Kim JO; Moon E; Huh YH; Lee SH; Jo EK; Cho SY; Lee JE; Chung C
Cancer Med; 2021 Feb; 10(4):1405-1417. PubMed ID: 33486901
[TBL] [Abstract][Full Text] [Related]
16. Serum α-1 Acid Glycoprotein is a Biomarker for the Prediction of Targeted Therapy Resistance in Advanced EGFR-positive Lung Adenocarcinoma.
Xu YF; Xu Y; Li X; Yang XM
Comb Chem High Throughput Screen; 2018; 21(10):755-759. PubMed ID: 30663564
[TBL] [Abstract][Full Text] [Related]
17. miR-608 and miR-4513 significantly contribute to the prognosis of lung adenocarcinoma treated with EGFR-TKIs.
Zhang N; Li Y; Zheng Y; Zhang L; Pan Y; Yu J; Yang M
Lab Invest; 2019 Apr; 99(4):568-576. PubMed ID: 30552364
[TBL] [Abstract][Full Text] [Related]
18. Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.
Tohmé R; Izadmehr S; Gandhe S; Tabaro G; Vallabhaneni S; Thomas A; Vasireddi N; Dhawan NS; Ma'ayan A; Sharma N; Galsky MD; Ohlmeyer M; Sangodkar J; Narla G
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830869
[TBL] [Abstract][Full Text] [Related]
19. HCP5 is a SMAD3-responsive long non-coding RNA that promotes lung adenocarcinoma metastasis via miR-203/SNAI axis.
Jiang L; Wang R; Fang L; Ge X; Chen L; Zhou M; Zhou Y; Xiong W; Hu Y; Tang X; Li G; Li Z
Theranostics; 2019; 9(9):2460-2474. PubMed ID: 31131047
[No Abstract] [Full Text] [Related]
20. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor.
Rong X; Liang Y; Han Q; Zhao Y; Jiang G; Zhang X; Lin X; Liu Y; Zhang Y; Han X; Zhang M; Luo Y; Li P; Wei L; Yan T; Wang E
J Thorac Oncol; 2019 Oct; 14(10):1766-1783. PubMed ID: 31228625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
